HK1211474A1 - Treatment of immune-related and inflammatory diseases - Google Patents

Treatment of immune-related and inflammatory diseases

Info

Publication number
HK1211474A1
HK1211474A1 HK15112280.7A HK15112280A HK1211474A1 HK 1211474 A1 HK1211474 A1 HK 1211474A1 HK 15112280 A HK15112280 A HK 15112280A HK 1211474 A1 HK1211474 A1 HK 1211474A1
Authority
HK
Hong Kong
Prior art keywords
immune
treatment
inflammatory diseases
inflammatory
diseases
Prior art date
Application number
HK15112280.7A
Other languages
English (en)
Chinese (zh)
Inventor
彼得‧
‧謝弗
拉傑什‧喬普拉
阿尼塔‧甘地
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of HK1211474A1 publication Critical patent/HK1211474A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK15112280.7A 2012-08-09 2015-12-14 Treatment of immune-related and inflammatory diseases HK1211474A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261681491P 2012-08-09 2012-08-09
US201261722718P 2012-11-05 2012-11-05
PCT/US2013/054051 WO2014025958A2 (en) 2012-08-09 2013-08-08 Treatment of immune-related and inflammatory diseases

Publications (1)

Publication Number Publication Date
HK1211474A1 true HK1211474A1 (en) 2016-05-27

Family

ID=49029213

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112280.7A HK1211474A1 (en) 2012-08-09 2015-12-14 Treatment of immune-related and inflammatory diseases

Country Status (30)

Country Link
US (2) US10919883B2 (pt)
EP (2) EP2882441B1 (pt)
JP (2) JP6250671B2 (pt)
KR (3) KR102266509B1 (pt)
CN (4) CN108938642A (pt)
AU (1) AU2013299625B2 (pt)
BR (1) BR112015002272A2 (pt)
CA (2) CA2881113C (pt)
CY (1) CY1123106T1 (pt)
DK (1) DK2882441T3 (pt)
EA (1) EA029085B1 (pt)
ES (1) ES2800026T3 (pt)
HK (1) HK1211474A1 (pt)
HR (1) HRP20200836T1 (pt)
HU (1) HUE049569T2 (pt)
IL (1) IL237070B (pt)
LT (1) LT2882441T (pt)
MX (1) MX2015001686A (pt)
NI (1) NI201500013A (pt)
NZ (2) NZ628077A (pt)
PH (1) PH12015500276A1 (pt)
PL (1) PL2882441T3 (pt)
PT (1) PT2882441T (pt)
RS (1) RS60416B1 (pt)
SG (1) SG11201500983RA (pt)
SI (1) SI2882441T1 (pt)
TW (1) TWI641371B (pt)
UA (1) UA116992C2 (pt)
WO (1) WO2014025958A2 (pt)
ZA (1) ZA201500466B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3202460T (pt) 2010-02-11 2019-08-05 Celgene Corp Derivados arilmetoxi-indolina e composições que os compreendem e métodos para a sua utilização
WO2012135299A1 (en) 2011-03-28 2012-10-04 Deuteria Pharmaceuticals Inc 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
AU2014205043B2 (en) 2013-01-14 2018-10-04 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
WO2014152833A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
EP3145513B1 (en) * 2014-05-19 2023-11-15 Celgene Corporation 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
WO2015179279A1 (en) * 2014-05-19 2015-11-26 Celgene Corporation Treatment of immune-related and inflammatory diseases
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
EP3496739B1 (en) 2016-07-15 2021-04-28 Acceleron Pharma Inc. Compositions comprising actriia polypeptides for use in treating pulmonary hypertension
CN112839658A (zh) 2018-10-01 2021-05-25 细胞基因公司 用于治疗癌症的组合疗法
US11255850B2 (en) 2019-03-28 2022-02-22 Alentic Microscience Inc. Bead-based analysis of a sample
US10684278B1 (en) * 2019-03-28 2020-06-16 Alentic Microscience Inc. Bead-based analysis of a sample
US11719700B2 (en) 2019-03-28 2023-08-08 Alentic Microscience Inc. Upconversion for microscopy
US11609233B2 (en) 2019-03-28 2023-03-21 Alentic Microscience Inc. Indicator-based analysis of a sample
WO2021108303A1 (en) * 2019-11-25 2021-06-03 PHPrecisionMed, LLC Pharmaceutical compositions for the treatment of pulmonary hypertension
WO2023097111A2 (en) * 2021-11-29 2023-06-01 Riptide Bioscience, Inc. Methods and compositions for treating calcinosis associated conditions
WO2024064646A1 (en) 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
HU196714B (en) 1984-10-04 1989-01-30 Monsanto Co Process for producing non-aqueous composition comprising somatotropin
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
EP0835101B1 (en) 1995-06-27 2004-06-09 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
US6197350B1 (en) 1996-12-20 2001-03-06 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
BR9908811A (pt) 1998-03-16 2000-12-05 Celgene Corp Composto, composição farmacêutica e seu uso no tratamento de mamìferos
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
AU1325102A (en) 2000-10-16 2002-04-29 Phylos Inc Protein scaffolds for antibody mimics and other binding proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2444854A1 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
GB0120441D0 (en) 2001-08-22 2001-10-17 Novartis Forschungsstiftung Model of autoimmune disease and methods for identifying anti autoimmune disease disorders
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
AU2005307789A1 (en) 2004-11-16 2006-05-26 Avidia Research Institute Protein scaffolds and uses thereof
US8088591B2 (en) * 2006-05-12 2012-01-03 University Of Miami Biomarkers for detection and diagnosis of head and neck squamous cell carcinoma
US20080045485A1 (en) 2006-08-17 2008-02-21 Peter Muir Methods of diagnosing synovial disease in a mammal by detecting bacterial DNA in synovial tissues from dogs with inflammatory knee arthritis and degenerative anterior cruciate ligament rupture
BRPI0720043A2 (pt) * 2006-12-15 2014-01-07 Abbott Lab Composto oxadiazol
AR065810A1 (es) 2007-03-20 2009-07-01 Celgene Corp Derivados de isoindolina 4'-o-sustituidos,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer y en otros trastornos donde es necesario el control de la angiogenesis o la inhibicion de citoquinas, incluyendo tnf-alfa.
EP2132568B1 (en) 2007-03-30 2013-05-29 Chu Sainte-justine Method of determining risk of scoliosis
JP5442185B2 (ja) * 2007-04-24 2014-03-12 日本メナード化粧品株式会社 感作性物質評価方法
WO2009124064A1 (en) 2008-03-31 2009-10-08 Boston Medical Center Corporation Predictive marker for topoisomerase i inhibitors
JP2011522515A (ja) * 2008-04-10 2011-08-04 マサチューセッツ インスティテュート オブ テクノロジー 癌幹細胞を標的とする薬剤を同定する方法およびその使用
CA2744711C (en) * 2008-12-05 2017-06-27 Abbott Laboratories Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
BRPI1011394A8 (pt) 2009-04-18 2018-06-26 Genentech Inc método para avaliação de responsividade de linforma de células b ao tratamento com anticorpos anti-cd40
PT3202460T (pt) * 2010-02-11 2019-08-05 Celgene Corp Derivados arilmetoxi-indolina e composições que os compreendem e métodos para a sua utilização
JP5808349B2 (ja) * 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
WO2012024543A1 (en) 2010-08-18 2012-02-23 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
CN103492590A (zh) * 2011-02-22 2014-01-01 卡里斯生命科学卢森堡控股有限责任公司 循环生物标志物
CA2839530A1 (en) * 2011-06-16 2012-12-20 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
CA3136093A1 (en) 2012-06-29 2014-01-03 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
US20140343058A1 (en) 2012-08-09 2014-11-20 Celgene Corporation Treatment of systemic lupus erythematosus
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
EP3145513B1 (en) 2014-05-19 2023-11-15 Celgene Corporation 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus

Also Published As

Publication number Publication date
EP2882441B1 (en) 2020-04-29
CA2881113C (en) 2020-10-27
TWI641371B (zh) 2018-11-21
JP2015527349A (ja) 2015-09-17
RS60416B1 (sr) 2020-07-31
EA029085B1 (ru) 2018-02-28
CA3092279C (en) 2023-08-08
KR20200058606A (ko) 2020-05-27
UA116992C2 (uk) 2018-06-11
KR102266509B1 (ko) 2021-06-16
JP2018070623A (ja) 2018-05-10
JP6250671B2 (ja) 2017-12-20
ES2800026T3 (es) 2020-12-23
LT2882441T (lt) 2020-07-27
EA201590342A1 (ru) 2015-07-30
CN104703605A (zh) 2015-06-10
EP3741372A1 (en) 2020-11-25
KR102118559B1 (ko) 2020-06-03
PL2882441T3 (pl) 2020-09-21
WO2014025958A2 (en) 2014-02-13
CA3092279A1 (en) 2014-02-13
ZA201500466B (en) 2016-06-29
TW201408298A (zh) 2014-03-01
KR20150039848A (ko) 2015-04-13
CN115068484A (zh) 2022-09-20
SG11201500983RA (en) 2015-04-29
EP2882441A2 (en) 2015-06-17
PH12015500276A1 (en) 2015-04-27
NI201500013A (es) 2019-05-10
NZ727295A (en) 2018-06-29
WO2014025958A3 (en) 2014-04-17
AU2013299625A1 (en) 2015-02-12
CA2881113A1 (en) 2014-02-13
HRP20200836T1 (hr) 2020-08-07
BR112015002272A2 (pt) 2017-07-04
JP6595565B2 (ja) 2019-10-23
KR20210073616A (ko) 2021-06-18
CY1123106T1 (el) 2021-10-29
CN114939119A (zh) 2022-08-26
IL237070A0 (en) 2015-03-31
PT2882441T (pt) 2020-06-29
US10919883B2 (en) 2021-02-16
SI2882441T1 (sl) 2020-08-31
DK2882441T3 (da) 2020-05-25
AU2013299625B2 (en) 2018-02-01
CN108938642A (zh) 2018-12-07
NZ628077A (en) 2017-04-28
IL237070B (en) 2019-06-30
HUE049569T2 (hu) 2020-09-28
US20140045844A1 (en) 2014-02-13
MX2015001686A (es) 2015-04-10
US20210340132A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
HK1211474A1 (en) Treatment of immune-related and inflammatory diseases
HK1207399A1 (en) Methods and processes for non-invasive assessment of genetic variations
HK1206794A1 (en) Methods and processes for non-invasive assessment of genetic variations
HK1205203A1 (en) Methods and processes for non-invasive assessment of genetic variations
HK1206055A1 (en) Methods and processes for non-invasive assessment of genetic variations
HK1207701A1 (en) Methods and processes for non-invasive assessment of genetic variations
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
EP2912178A4 (en) SUPER AMPLIFIER AND METHOD FOR USE THEREOF
ZA201301601B (en) Treatment of diseases
EP2613786A4 (en) TREATMENT OF DISEASES
HK1200348A1 (en) Methods and materials for treatment of pompes disease
EP2723347A4 (en) PREVENTING AND TREATING INFLAMMATORY DISEASES
EP2852397A4 (en) HUWENTOXIN IV VARIANTS AND METHODS OF USE
HK1211213A1 (en) Treatment of diseases involving mucin
IL234606A0 (en) Innovative methods and compounds for the treatment of diseases
EP2844364A4 (en) SEALED SEAM FILTER AND METHOD OF MANUFACTURING THEREOF
HK1204573A1 (en) Treatment of inflammatory skin disorders
EP2585828A4 (en) METHOD FOR THE TREATMENT OF PATIENTS WITH IMMUNE SYSTEM DISEASES
PL2892556T3 (pl) Kompozycje i sposoby odnoszące się do leczenia chorób
EP2575824A4 (en) METHODS FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES
HK1211498A1 (en) Treatment of sickle cell disease and inflammatory conditions
EP2838509A4 (en) FORMULATIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES
GB2493595B (en) Wheelchair and method of construction
GB201221118D0 (en) Methods of treatment
GB201201778D0 (en) Treatment of inflammatory respiratory disease